Role of cyclin-dependent kinase 5 in psychosis and the modulatory effects of cannabinoids.
Marta Barrera-Conde, Emma Veza-Estévez, Maria Gomis-Gonzalez, Jordi Garcia-Quintana, Amira Trabsa, Laura Martínez-Sadurní, Mitona Pujades, Víctor Perez, Rafael de la Torre, Daniel Bergé, Patricia Robledo
Neurobiology of Disease 2023 DOI: 10.1016/j.nbd.2022.105942 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case-control study with in vitro and animal model Peer reviewed |
|---|---|
| Population | First-episode psychosis patients with and without prior cannabis use, and adolescent mice |
| Interventions | WIN-55 212-2 Phencyclidine Roscovitine |
| Dose | WIN: 1 mg/kg; PCP: 10 mg/kg |
| Duration | WIN-55,212-2 for 21 days; phencyclidine for 10 days |
| Topics | Cannabis |
| Keywords | First-episode psychosis Human olfactory neuroepithelium Mice models Phencyclidine |
| Key findings | First-episode psychosis patients with prior cannabis use had lower CDK5 and higher PSD95 levels and less social functioning deficits than non-users, and CDK5 blockade in mice reversed social impairments. |
Abstract
Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase that has emerged as a key regulator of neurotransmission in complex cognitive processes. Its expression is altered in treated schizophrenia patients, and cannabinoids modulate CDK5 levels in the brain of rodents. However, the role of this kinase, and its interaction with cannabis use in first-episode psychosis (FEP) patients is still not known. Hence, we studied the expression changes of CDK5 and its signaling partner, postsynaptic density protein 95 (PSD95) in olfactory neuroepithelial (ON) cells of FEP patients with (FEP/c) and without (FEP/nc) prior cannabis use, and in a dual-hit mouse model of psychosis. In this model, adolescent mice were exposed to the cannabinoid receptor 1 agonist (CB1R) WIN-55,212-2 (WIN: 1 mg/kg) during 21 days, and to the N-methyl-d-aspartate receptor (NMDAR) blocker phencyclidine (PCP: 10 mg/kg) during 10 days. FEP/c showed less social functioning deficits, lower CDK5 and higher PSD95 levels than FEP/nc. These changes correlated with social skills, but not cognitive deficits. Consistently, exposure of ON cells from FEP/nc patients to WIN in vitro reduced CDK5 levels. Convergent results were obtained in mice, where PCP by itself induced more sociability deficits, and PSD95/CDK5 alterations in the prefrontal cortex and hippocampus than exposure to PCP-WIN. In addition, central blockade of CDK5 activity with roscovitine in PCP-treated mice restored both sociability impairments and PSD95 levels. We provide translational evidence that increased CDK5 could be an early indicator of psychosis associated with social deficits, and that this biomarker is modulated by prior cannabis use.
Comparable studies
Other preclinical and animal studies on cannabis, most cited first.
Citations in the library
Cites 10
- Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors PLoS Biology July 9, 2015
- Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study. Drug and Alcohol Dependence October 1, 2021
- Exploring the relationship between recency and frequency of cannabis use and diminished expression and apathy as two dimensions of negative symptoms in first episode psychosis. A one-year follow-up study. Schizophrenia Research August 25, 2021
- Symptomatology and neurocognition among first-episode psychosis patients with and without cannabis use in the three months prior to first hospitalization. Schizophrenia Research January 9, 2021
- The relationship between cannabis use and cognition in people diagnosed with first-episode psychosis. Psychiatry Research August 23, 2020
and 5 more in the library